Full-Time
Director of Office of the CEO
Founder in Residence
BillionToOne
501-1,000 employees
QCT-based molecular diagnostics for prenatal, oncology
Compensation Overview
$203.7k - $225.1k/yr
Menlo Park, CA, USA
Hybrid
Relocation to the SF Bay Area required; hybrid with 3 on-site days per week.
 Business & Strategy (1) |
|---|
Get referred to BillionToOne
See people who can refer or advise you
- 6-10+ years of building or operating experience, with a track record of exceptional impact in entrepreneurial or builder-oriented environments
- One of the following backgrounds: founder of a company that has since been acquired, wound down, or moved on from; senior executive (COO, CPO, VP-level) who joined a top scaleup as one of its first 5 to 10 employees; or top-tier management consultant from MBB or a top boutique firm with healthcare or life sciences exposure, with some operational experience under your belt.
- First-principles thinker with exceptional analytical horsepower
- Builder mentality — bias to action, comfort with ambiguity, ability to operate without a playbook
- AI-native fluency in using AI tools to move faster and amplify individual leverage
- Strong written and verbal communication, including with executives and the Board
- Genuine interest in molecular diagnostics and the BillionToOne mission
- On-site position (relocation to SF Bay Area required)
- Own CEO-Priority Projects: Lead one or more of BillionToOne's highest-priority strategic and operational initiatives each quarter, sourced directly from the CEO and Office of the CEO. Project types span new product launch support, commercial and go-to-market strategy, business development, operational excellence, competitive response, and the incubation of new business lines.
- Find Broken Things and Fix Them: Identify under-performing processes, workflows, or functions. Diagnose root cause, design the fix, and drive execution end-to-end with cross-functional teams.
- Cross-Functional Leadership: Lead and influence cross-functional teams across Sales, Product, Lab Operations, Compliance, Reimbursement, Finance, BD, Legal, and HR. Build deep working knowledge of how each function operates through the projects you lead.
- Operate with AI: Drive results in ambiguous, fast-moving environments. Use first-principles thinking and AI-native fluency to move faster than the company would otherwise be able to.
- CEO and Executive Partnership: Participate in CEO meetings, present to the executive team on an ongoing basis, and serve as a trusted thought partner to the CEO and Chief of Staff on company-shaping decisions.
- Prior exposure to healthcare, life sciences, molecular diagnostics, or other regulated industries
- Track record of building 0 to 1 — new products, new functions, new business lines, or new operating mechanisms
- Existing network in the founder community, YC ecosystem, or top scaleup operating community
BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
2016
Get referred to BillionToOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $109.4 million, up 64%, with 70% gross margin.
- August 17, 2026 launches add a 130-gene Unity panel and expand prenatal reach.
- June 2026 oncology data and July CMO hires strengthen Northstar commercialization.
What critics are saying
- After Q2, shares fell nearly 30%, exposing valuation fragility around guidance.
- Oncology growth depends on MolDX coverage for Northstar Response by late 2026.
- If MolDX rejects Northstar Response, oncology remains a marginal side business.
What makes BillionToOne unique
- Unity Confirm pairs fetal cell capture with noninvasive confirmation after high-risk screening.
- Northstar Select now offers 84 genes, and Northstar Origin adds tissue-of-origin.
- BillionToOne counts single DNA molecules, enabling rare-variant detection at low fractions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -1%2 year growth
↑ 0%BillionToOne, a molecular diagnostics company, reported second-quarter 2026 revenue of $109.4 million, up 64% from $66.6 million in the same period last year. Prenatal clinical testing revenue reached $94.2 million, whilst oncology testing revenue surged 176% to $13.7 million. The company delivered 196,000 tests during the quarter, a 35% increase year-over-year. Gross profit margin improved to 70% from 65%. BillionToOne posted operating income of $5.5 million, compared to a $1.6 million loss in Q2 2025. The firm reiterated its full-year 2026 revenue guidance of $450 million to $465 million, representing 48% to 52% growth over 2025. BillionToOne announced plans to expand its Unity Fetal Risk Screen with a 130-gene panel launching 17 August 2026.
BillionToOne reported strong second-quarter results for 2026, with total revenue reaching $109.4 million, up 64% year-over-year. Prenatal revenue rose 56% to $95.8 million, while oncology revenue surged 176% to $13.7 million. The company achieved gross margins of 70.5%, up 5 percentage points from the previous year. BillionToOne posted operating income of $5.5 million and net income of $8.1 million, or $0.15 per diluted share. Test volumes increased 35% year-over-year to approximately 196,000 tests, with average selling prices rising 21% to $551 per test. The company generated $9.1 million in cash from operations and $5.1 million in free cash flow. BillionToOne maintained its full-year 2026 revenue guidance of $450 million to $465 million.
BillionToOne to launch NIPT, liquid biopsy add-ons as Q2 revenue rises 64 percent. NEW YORK - BillionToOne said on Wednesday that its second-quarter revenue grew 64 percent year over year on the back of strong prenatal and oncology clinical testing sales. Get the full story with GenomeWeb Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month Already a GenomeWeb member? LoginLogin
Perceptive Advisors LLC has $7.25 million stock position in Billiontoone, Inc. $BLLN. August 2, 2026 Key points. * Perceptive Advisors increased its Billiontoone stake by 26.1% in the first quarter, holding 91,812 shares worth approximately $7.25 million. Several other institutional investors also initiated or expanded positions. * Billiontoone reported a strong quarter, with revenue rising 83.8% year over year to $108.39 million and adjusted earnings of $0.34 per share, beating the $0.01 consensus estimate. * Shares opened at $138.60, near their 12-month high, while insiders sold about $16.8 million of stock during the last quarter. Analysts maintain a "Moderate Buy" consensus with an average price target of $126. * MarketBeat previews top five stocks to own in September. Perceptive Advisors LLC raised its holdings in Billiontoone, Inc. (NASDAQ:BLLN - Free Report) by 26.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 91,812 shares of the company's stock after purchasing an additional 19,000 shares during the quarter. Perceptive Advisors LLC owned 0.20% of Billiontoone worth $7,248,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors also recently modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of Billiontoone by 8,603.4% during the 1st quarter. Bank of America Corp DE now owns 12,707 shares of the company's stock worth $1,003,000 after buying an additional 12,561 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Billiontoone by 151.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company's stock worth $2,408,000 after buying an additional 18,389 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Billiontoone in the first quarter valued at about $4,046,000. Public Employees Retirement System of Ohio bought a new position in Billiontoone in the first quarter valued at about $1,539,000. Finally, Sei Investments Co. bought a new position in Billiontoone in the first quarter valued at about $1,058,000. Billiontoone stock performance. Shares of Billiontoone stock opened at $138.60 on Friday. The stock has a market cap of $6.37 billion and a price-to-earnings ratio of 252.00. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $140.21. The company's fifty day moving average is $113.36 and its 200 day moving average is $93.29. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Billiontoone (NASDAQ:BLLN - Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. The firm's revenue for the quarter was up 83.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.39) earnings per share. Sell-side analysts forecast that Billiontoone, Inc. will post 0.92 EPS for the current year. Insider buying and selling. In related news, CTO David Tsao sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00. Following the sale, the chief technology officer directly owned 1,000 shares in the company, valued at $102,270. This represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 1,416 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $120.00, for a total transaction of $169,920.00. Following the sale, the senior vice president directly owned 33,552 shares of the company's stock, valued at $4,026,240. This represents a 4.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 153,049 shares of company stock valued at $16,768,021. Corporate insiders own 50.22% of the company's stock. Analyst Ratings changes. A number of research analysts have recently commented on BLLN shares. Guggenheim assumed coverage on shares of Billiontoone in a report on Monday, June 29th. They issued a "buy" rating and a $125.00 target price for the company. JPMorgan Chase & Co. lifted their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. BTIG Research lowered their price objective on shares of Billiontoone from $140.00 to $130.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Billiontoone from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00. Discover more MarketBeat Portfolio Tools Stock Average Calculator Billiontoone company profile. BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company's platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical. BillionToOne's offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Billiontoone, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Billiontoone wasn't on the list. While Billiontoone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
BillionToOne has appointed Ethan Dmitrovsky as Chief Medical Officer for Oncology to lead medical strategy for its Northstar liquid biopsy portfolio. Dmitrovsky joins from the Frederick National Laboratory for Cancer Research, where he served as Laboratory Director and President of Leidos Biomedical Research. He previously held senior positions at the University of Texas MD Anderson Cancer Center and Dartmouth's Geisel School of Medicine. Dmitrovsky's career includes establishing curative therapy for acute promyelocytic leukaemia, work that led to FDA approval. The Menlo Park-based molecular diagnostics company's Northstar portfolio includes therapy selection and response monitoring tests for solid tumours. Dmitrovsky will guide the platform's clinical adoption and lead BillionToOne's entry into the minimal residual disease space.